This exploratory subgroup analysis of the TAGS study assessed the efficacy, safety, and quality of life (QOL) results observed in patients who received trifluridine/tipiracil or placebo in the third- or later-line settings.
Investigators of the phase 1b/2 PANTHERA trial presented updated clinical and molecular profiling data from 43 patients who received frontline pembrolizumab, trastuzumab, and chemotherapy.
Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
A meta-analysis of randomized controlled trials found that there are significant risks for severe or fatal adverse events with ramucirumab, with only modest improvements in OS or PFS.
T-DXd treatment was associated with a better ORR and prolonged OS compared with standard chemotherapy with either irinotecan or paclitaxel.
Adjuvant treatment of GIST with imatinib for 36 months prolonged OS and RFS compared with 12 months of imatinib, according to data from nearly 10 years of follow-up.
These study findings show that weight loss occurred early among patients with advanced gastric cancer and was associated with shorter overall survival.
Ontruzant is supplied in 150 mg single-dose vials and 420 mg multidose vials.
ERAS clinical pathways typically involve early ambulation, and the early introduction of liquid and solid diets following surgery.
Fewer treatment-related grade 3 or higher adverse events were reported in the avelumab arm compared with the chemotherapy arm.
